
Eli Lilly’s heart drug underwhelms with REWIND trial
pharmafile | June 11, 2019 | News story | Manufacturing and Production | Eli Lilly, Trulicity, pharma
Eli Lilly’s Trulicity (dulaglutide) reduced major cardiovascular events (MACE) by 12% versus placebo in adults with type 2 diabetes, according to the results of the REWIND trial.
The study of 9901 adults with type 2 diabetes looked at the glucagon-like peptide 1 receptor agonist Trulicity in combination with standard of care treatment in comparison to standard of care treatment combined with placebo.
While Lilly’s drug was effective in reducing major cardiovascular events the drug failed to meet the expectations of investors. According to MarketWatch Cowen analysts said investors had expected at least 20% risk reduction.
Shares in the Indianapolis-based firm fell by 2.4% in premarket trading.
Louis Goss
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …






